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The ability to replace organs and tissues on-demand could save or improve millions of lives each year 
globally and create public health benefits on par with curing cancer. Unmet needs for organ and tissue 
preservation place enormous logistical limitations on transplantation, regenerative medicine, drug 
discovery and a variety of rapidly advancing areas spanning biomedicine. A growing coalition of 
researchers, clinicians, advocacy organizations, academic institutions and other stakeholders has 
assembled to address the unmet need for preservation advances, outlining remaining challenges and 
identifying areas of underinvestment and untapped opportunities. Meanwhile, recent discoveries provide 
proofs of principle for breakthroughs in a family of research areas surrounding biopreservation. These 
developments indicate that a new paradigm, integrating multiple existing preservation approaches and 
new technologies that have flourished in the past 10 years, could transform preservation research. 
Capitalizing on these opportunities will require engagement across many research areas and stakeholder 
groups. A coordinated effort is needed to expedite preservation advances that can transform several 
areas of medicine and medical science. 
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The global shortage of organs for transplantation has long been recognized as a major public health challenge, 
and the World Health Organisation (Geneva, Switzerland) estimates that only 10% of the worldwide need for 
organ transplantation is being met1. The data suggest that the organ shortage is among the greatest crises facing 
biomedicine today; although studies are needed to estimate the total number of patients who could benefit from 
organ transplantation if supply constraints were removed, common estimates based on transplant waitlists 
clearly fail to capture the organ shortage’s true magnitude. For example, the number of patients added to US 
transplant waitlists each year—roughly 50,000—is dwarfed by the ~730,000 annual US deaths attributable to 
end-stage organ disease (Fig. 1)2,3. It has been estimated that with all supply constraints removed, organ 
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replacement could theoretically prevent >30% of all deaths in the United States—doubling the average person’s 
likelihood of living to 80 years of age4–6. The organ shortage is markedly worse in developing countries. For 
instance, the continent of Africa holds 16% of the world’s population but performs only 0.5% of its organ 
transplants (Fig. 2). AU: 1) AS PER REV#2 CLARIFY IT IS NOT ONLY PRESERVATION THAT 
CONTRIBUTES BUT ALSO  HEALTHCARE INFRASTRUCTURE/PRIORITIES  
AU: 2) PLEASE ADD SOME CONTEXT AS TO TRANSPLANT TOURISM AND DECLARATION OF 
ISTANBUL AS REQUESTED BY REV#1 
This alone should place technologies to increase the quality and availability of transplant organs at the 
top of our scientific priority list. Moreover, the need for these technologies is shared with many other major 
public health challenges. Banking of viable organs and tissues can transform cancer treatment for young 
patients and dramatically impact precision medicine and research on diseases such as heart disease, cancer and 
Alzheimer’s disease. Ballooning costs in drug discovery are exacerbated by poor availability of human tissue 
models, which in many cases could provide more valuable data than the animal models currently used. Tissue 
transplantation faces enormous logistical barriers in emergency care due to the short time windows in which the 
tissue is needed. These challenges are magnified in contexts where large numbers of patients require care, such 
as the treatment of wounded service members and civilian victims of natural disasters or terrorist attacks. In 
these and many other areas, adequate techniques and treatments often already exist. However, their use is 
pervasively handicapped by the limited availability of organs and tissues, which are among research and 
medicine’s most precious resources. The aggregate toll on human health attributable to causes that could be 
addressed by increasing organ and tissue availability makes this problem one of the most important healthcare 
challenges of this era.  
Developing an organ and tissue supply that can meet the healthcare demands of the 21st century requires 
the development of solutions to twin challenges: first, having enough of these lifesaving resources; and second, 
having the means to store and transport them for a variety of applications, each with distinct but overlapping 
logistical needs. The first challenge of having enough organs and tissues to meet public health needs has been 
the subject of extensive efforts in science, medicine and public policy aiming to increase organ donation7,8, 
improve donor organ utilization9–12 and gain the understanding needed to engineer laboratory-grown tissues13, 
bio-artificial organs14,15 and ‘humanized’ animal donor organs for transplantation16,17. The success of these 
efforts is intertwined with meeting the second challenge: preserving organs and tissues during procurement (or 
manufacturing), storage, transport, and other steps of the supply chain in order to meet logistical needs.  
Despite its importance, the preservation challenge has received relatively little attention from funding 
agencies, the research community and the general public. Taken together, preservation constraints place 
widespread burdens on efforts to use organs and tissues in transplantation, regenerative medicine and research. 
5 
 
Yet although >80% of the budget of the US National Institutes of Health’s (NIH; Bethesda, MD) goes to 
institutes with missions tied to unmet preservation needs110, and numerous other science agencies and 
stakeholder groups stand to benefit from preservation advances, to date no funding body has been charged with 
meeting the remaining technical challenges common to the preservation of organ and tissue systems. As a 
result, the past half-century has seen only incremental and relatively ad hoc investments to advance preservation 
technologies.  
By overcoming these institutional barriers and facilitating coordinated and cross-disciplinary research, it 
is now possible to dramatically accelerate progress in organ and tissue preservation using existing knowledge 
from a diverse array of fields. The past decade of progress has allowed us to understand and intervene in human 
physiology at the tissue and organ level as never before, with breakthroughs in nanotechnology, sequencing, 
imaging, ‘-omics’ approaches and other areas. These technologies can be used to build on proofs of principle 
for organ cryopreservation4,5,18–21, discoveries from organisms that can enter ‘suspended animation’ at subzero 
temperatures31–34, rapid advances in perfusion technologies22–30, and other advances.  
In light of these opportunities, a growing coalition of scientists, clinicians, policymakers, advocacy 
groups, academic institutions and industry representatives is assembling to accelerate progress in organ and 
tissue preservation. This has led to an extensive dialogue spanning over a year, which has included the first 
global Organ Banking Summit at Stanford, NASA Research Park and other locations5, a US National Science 
Foundation (NSF; Washington, DC)-supported ‘Roadmap to Organ Banking and Bioengineering’ Workshop4, a 
meeting hosted with Defense Advanced Research Projects Agency (DARPA; Washington, DC) leadership at 
the US Military Academy at West Point, New York, on a potential ‘Organs on Demand’ research program, a 
White House roundtable on organ banking and bioengineering, and a symposium and roundtable on emerging 
organ preservation technologies on Capitol Hill. At these events, stakeholders have begun to outline the vast 
public health needs, remaining technological challenges, institutional and infrastructural barriers, and untapped 
research opportunities surrounding efforts to eliminate preservation constraints on the use of organs and tissues 
in biomedicine18. These efforts aim to facilitate the advancement of preservation platforms allowing us to 
transport, repair, assess, bank, and even enhance the health and function of organs and a variety of tissues used 
in research and medicine. 
The diversity of authors of this article, with expertise spanning organ and tissue procurement and 
transplantation, preservation research, bioengineering, economics, trauma care, and regenerative medicine, 
reflects the breadth of need in this area—and the widespread concern that until preservation breakthroughs are 
pursued aggressively, many medical technologies will not come close to reaching their lifesaving potential. In 
the sections that follow, we describe how organ and tissue preservation can meet a variety of major public 
health needs. We also outline recent discoveries indicating that a revolution in organ and tissue preservation is 
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now achievable, propose a novel paradigm for preservation involving convergence of a family of existing 
approaches, and describe how technologies have the potential to make a new generation of preservation 
technologies feasible. Finally, we suggest ways that the research community can overcome institutional barriers 
that hinder advances and highlight recent progress toward a coordinated research effort. 
 
The unrealized potential of organ transplantation 
 
Organ transplantation is one of the most impressive medical achievements of the past century. In the past 25 
years, it has added over 2 million life years to patients in the United States alone35. In the 60 years, since its 
inception, researchers have made strides in drug-mediated immunosuppression36, achieved increasingly 
complex transplant operations37–39, and (recently) have begun to move immune tolerance induction therapies 
into the clinic40–43.  
Yet access to transplantation and its efficacy are still fundamentally constrained. In part because of the 
rare conditions that must exist for organs to be suitable for recovery and transplantation, today only 0.3% of 
those who die in the United States become organ donors3,44. Ideally, one organ donor can provide up to eight 
life-saving organs to patients on transplant waitlists, yet on average roughly only three are transplanted—
despite decades of progress advancing organ procurement protocols and heroic efforts by organ procurement 
organizations2,44. Although advances in immunosuppression have greatly increased transplant success rates and 
graft survival45–47, half of these organs fail within 10 years of being transplanted, including as much as 75% of 
intestines and lungs (Fig. 3)48. To delay rejection, transplant recipients must adhere to lifelong 
immunosuppressant drug regimes, the side effects of which put patients at increased risk for life-threatening 
infections as well as cancer and other major age-related diseases49. Meanwhile, children, ethnic minorities, and 
other vulnerable patient populations have markedly reduced access to transplantation50–53. The toll on the 
economy of failing to advance transplantation is immense; for instance, the worldwide cost of treating end-stage 
renal disease totals over $1 trillion in the course of a decade54, with over $40 billion spent by the United States 
in 2009 alone55. 
These problems are fueled by severe logistical constraints related to organ preservation limits. Although 
leaps forward in machine perfusion22–30,56–58, organ cryopreservation19,20,59, understanding mechanisms of 
ischemic injury and metabolic regulation30–34, and other areas have created a blueprint for transforming organ 
preservation, today maximum clinical organ preservation times are measured in hours and necessitate 
transplantation almost immediately after the organ is recovered (http://www.nedonation.org/donation-
guide/organ/acceptable-ischemic-times). Organs are rushed to their destinations, often by jet or by helicopter 
flight straight to a landing pad on the transplant center rooftop. Speed is essential when arranging and 
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performing the transplant surgery, leaving little room to adapt procedures to individual circumstances or deal 
with complications. Lengthy operations must be performed day or night with little advanced warning. These 
factors contribute to high costs for organ transplantation, which in the United States can average well over $1 
million (e.g., heart, intestine, and double lung transplant)60. During transplantation organs are exposed to a 
continuous barrage of inflammation and oxidative stress, both before and after organ procurement from the 
donor, contributing to immune rejection, delayed graft function, and other complications that harm transplant 
outcomes. 
Donor organs and recipients must be matched over relatively short geographic distances and time 
windows, often resulting in the use of organs that are immunologically less well matched to recipients. This 
puts patients at increased risk for organ rejection and contributes to the need for intense immunosuppressive 
regimens61. The increased rate and severity of rejection limits organ lifespan, further exacerbating the organ 
shortage; within several years of transplantation, many patients are in need of a new organ all over again48. 
Limited matching distances leave waitlist patients from different regions with unequal access to transplant 
organs as supply and need vary. These imbalances disproportionately affect patients with fewer resources, who 
cannot relocate to join more favorable waitlists50,62. Matching limitations often fall hardest on populations with 
small pools of potential matching donors, particularly among children and ethnic minorities51,52,63,64. 
 Meanwhile, narrow windows for organ assessment, allocation, and transplantation fuel organ discard. 
Organs are offered to individual waitlist patients, whose doctors must decide whether to recommend 
transplantation based on limited information about the organ’s suitability for transplantation; with little 
information on the organ’s functional status, some patients may turn it down when the donor’s history or other 
indicators are dubious, waiting until a less risky organ is (hopefully) made available. Even a functional, 
transplantable organ may be turned down by one patient’s transplant center after another until the organ’s 
preservation limits prevent further matching30,65. Each year, this phenomenon contributes to thousands of 
abdominal organs being discarded65,66 and the majority of thoracic organs from donors (~70% of heart and 80% 
of lung offers) going untransplanted2,67. Most likely, many of these organs could have been successfully 
transplanted under the right circumstances30,68–70. The resulting impact on waitlist patients is profound. In the 
United States, if just 10% of the number of donor hearts currently left unused were transplanted, the number of 
additional hearts made available would equal the number of waitlist patients who currently die or become too 
sick for a transplant before receiving one (Table 1)66.  
 
Organ transplantation without preservation constraints 
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A successful large-scale organ preservation research effort would create a very different world for organ 
transplantation, creating a breadth of new capabilities that can make more organs available, improve transplant 
outcomes and mitigate risks, decrease costs, and complement and accelerate the development of other 
biomedical technologies that can alter the landscape of transplantation in the coming years (see Table 2). For 
instance, preservation advances can build on promising strategies that use perfusion circuits to mimic healthy 
physiological conditions23,71,72, allowing the organ to recover from the stresses of donor death and organ 
procurement and enabling therapeutic intervention before transplantation. These platforms could make larger 
pools of donor organs available by enabling rehabilitation of organs that would otherwise be unsuitable for 
transplantation27,30,73. 
Perfusion-based preservation could be harnessed as a platform to functionally enhance organs, for 
instance by drug-mediated immunomodulation (applying treatments that block or alter sites recognized by the 
recipient immune system to mitigate rejection)74,75, gene therapy76,77, antisense or RNA interference to 
condition organs for transplantation or subsequent steps of the preservation process78. Similar interventions 
could even be used to improve organs’ health and function, making them in some ways healthier in the recipient 
than they were in the donor. For instance, perfusion platforms have allowed the ‘defatting’ of livers after 
removal in models of steatosis,30 showing promise to mitigate or reverse organ degeneration during the donor’s 
lifetime that could otherwise affect both transplant outcomes and later recipient health9,79,80. 
Perfusion platforms can allow transplantation of many organs that would otherwise be deemed too risky 
to transplant by allowing their health and function to be assessed outside the body26,30,77,81,82. For example, it has 
been proposed by the National Heart Lung and Blood Institute (NHLBI; Bethesda, MD) and indicated by other 
studies that many hearts that would provide substantial survival benefits to patients are going unused, largely 
due to a lack of reliable methods to assess their suitability for transplantation70,83. By allowing organ function to 
be observed after procurement, perfusion platforms are enabling the investigation of new biomarkers that 
predict organ health and transplantability84–87. 
A variety of preservation breakthroughs could enable transport of organs over longer distances5,29, 
opening up many new possibilities for organ allocation and therapeutic intervention. With distance no longer a 
factor in donor–recipient matching, closer matches could be achieved. This could decrease rejection and the 
need for immunosuppression61 and extend graft lifespan, while increasing access to transplantation for 
disadvantaged patient populations51,64. Organs could also be routed through specialized facilities, which have 
been suggested by several groups as a way to make technically challenging assessment, repair, functional 
augmentation, or banking procedures a clinical reality5,77,82. Thus, approaches that today would not be seriously 
considered could become practical and fruitful areas of innovation. 
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Preservation breakthroughs could allow organs to be banked in a state of suspended animation at 
subzero temperatures5,18–20,59, protected from ischemic injury and the damaging environment of the deceased 
donor body, for periods long enough to perform any assay needed on patients or tissue samples. This would 
enable more thorough screening for malignancies and transmissible diseases, such as rabies89,90 and HIV91. 
Currently, disease transmission rates in organ transplantation, although less than 1%, are estimated to be on the 
order of 10,000 times higher than in blood transfusion where a maximum shelf life of 5–6 weeks enables the use 
of lengthy disease screening assays92. Organ banking could also provide many new opportunities for matching 
by uncoupling organ allocation from the short time windows that currently constrain it.  
Importantly, organ banking could prevent unnecessary loss of life by allowing any organs not 
immediately matched to be saved until a match could be found. This would make transplantation available to 
more patients, not only by offering a complementary organ supply but also by shifting the risk–benefit balance 
for patients and their transplant centers away from refusing transplantable organs. Primary graft dysfunction is a 
major cause of morbidity and mortality following transplantation,93–95 and roughly 50–75% (depending on the 
organ transplanted) of all graft failure in the first year after transplantation occurs within the first three 
months48. Banked organs could provide a ‘backup’ supply in the case of early failure of the initial transplant; in 
cases where multiple matching organs were available, often multiple successive transplants would be feasible if 
the initial transplant fails. Thus, even when an organ individually carries a risk of early graft failure, the 
alternative supply of banked organs could substantially de-risk the overall process of transplantation, allowing 
transplant centers to accept the organ with substantially decreased patient risk.  AU: PLEASE ADDRESS 
REV#1 COMMENT “acceptable cold ischemic times vary as a function of the allograft type. Moreover, 
efforts to place organs from a single deceased donor may delay procurement. Peri-procurement tissue 
injury likely increases expression of cell surface markers which promote the inflammatory/immune 
response.” 
AU: PLEASE ALSO ADDRESS REV#1 SUGGESTION: authors mention morbidity and 
mortality for those who make it to the wait-list. With increased organ availability, death on the waiting 
list and perioperative mortality will decrease. The paper by Goldberg emphasizes existing disparities. 
Goldberg, D., French, B., Abt, P., Feng, S. and Cameron, A. M. (2012), Increasing disparity in waitlist 
mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular 
carcinoma versus candidates without hepatocellular carcinoma. Liver Transpl, 18: 434–443. 
doi:10.1002/lt.23394; Lai, J. C., Feng, S., Terrault, N. A., Lizaola, B., Hayssen, H. and Covinsky, K. 
(2014), Frailty Predicts Waitlist Mortality in Liver Transplant Candidates. American Journal of 
Transplantation, 14: 1870–1879. doi: 10.1111/ajt.12762 
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Organ banking could also make transplantation a lifesaving treatment for trauma patients, victims of 
accidental poisoning, and those with acute vital organ failure. For these patients, matching transplant organs 
need to be available within extremely short time windows necessitating off-the-shelf solutions. Banking the 
substantial fraction of organs that go unused in the current allocation system could be lifesaving for these 
patients. The public health benefits of banking organs for emergency surgery could be vast; traumatic injury 
accounts for more deaths among adolescents and children than all other causes combined96. Further 
advancement of banking, assessment, and repair capabilities could allow this approach to benefit ever larger 
patient populations.  
The ability to save organs not immediately matched could be useful in live donation as well. In the 
recent innovation of live kidney donor chains, transplants are arranged in long chains between incompatible 
donor−patient pairs, so that each patient in the chain receives a compatible kidney. However, chains end when 
no appropriate recipient can be immediately found for the last donor in the chain, who instead donates to an 
individual on the deceased donor waiting list without a corresponding donor to continue the chain97,98. The 
opportunity to delay transplantation could create wider opportunities to find a donor–recipient pair who can 
continue the chain, allowing longer chains to be assembled. 
Moreover, the ability to bank organs can aid in the development of technologies that could be game-
changers for transplantation. For instance, a diverse array of immune tolerance induction approaches could 
overcome graft rejection while largely eliminating the need for immune suppression. Currently, all successful 
clinical trials involve living donors, such that tolerance induction treatments can be initiated before 
transplantation40–43. Temporary banking of donor organs could enable tolerance induction for deceased donor 
organs (the vast majority of transplants) as well, by allowing the required pre-transplant preparative regimen to 
be administered to recipients before the organ transplant. This could give the patient’s immune system time to 
adapt to the donor’s antigens prior to transplantation, and it would also provide time to evaluate the success of 
tolerance induction protocols in a matched patient before transplantation.  
Meanwhile, longer-term efforts to create lab-grown organs via tissue engineering or xenotransplantation 
of ‘humanized’ donor animal organs would be aided by the ability to bank inventories to make these approaches 
practical and cost effective at scale. On the back of advances in immune tolerance induction16 and the advent of 
CRISPR/Cas9 gene editing methods that open the possibility of more complex genetic engineering of donor 
organs to make them less vulnerable to recipient immune rejection99, xenotransplantation could potentially offer 
a vast new source of transplant organs. But attainment of an engineered organ capable of engraftment and 
survival remains many years away and the investments required for clinical xenotransplantation are 
tremendous; large, centralized facilities would be required to produce transplant organs at scale, making cost 
effective manufacturing and distribution a major concern unless these organs can be banked17. Similarly, shelf 
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life has been widely recognized as a key bottleneck in the progress of tissue engineering (discussed 
below)4,100,101. 
 
Challenges in complex tissue preservation 
 
The same technologies (discussed below) that promise to transform vital organ preservation also advance the 
preservation of a vast array of tissue systems and address a large breadth of public health needs. Inadequate 
tissue preservation capabilities are a constraint on basic and preclinical biomedical research aimed at addressing 
major illnesses, drug testing and drug development, trauma care, stockpiling of medical countermeasures for 
large-scale public health emergencies, fertility restoration, as well as the advancement of tissue engineering and 
regenerative medicine (see Table 3 for examples). 
Tissue engineering and regenerative medicine. Current preservation limits present major challenges 
for the clinical translation of tissue engineering breakthroughs. Without the ability to increase shelf life, any 
attempt to develop biomanufactured tissue products lack capabilities for batch manufacturing and distribution 
while facing difficulties adjusting to changing demand6,13,102–104. Short product shelf lives also prevent 
implementation of some methods for quality control for tissue and organ products, adding substantial cost and 
risk6,13,103,104.  
Opportunities abound to enhance banking capabilities for tissue engineering. For instance, successful 
cryopreservation of a 2.3 liter biomass for use in a bioartificial liver device may stimulate research on other 
large volume tissue engineered products105. These challenges have led the US Commerce Department 
(Washington, DC), Department of Defense (DoD; Washington, DC), and the US government’s Multi-Agency 
Tissue Engineering Sciences (MATES; Washington, DC) working group coordinating tissue engineering 
research support across NIH, NSF, the US National Institute of Standards and Technology (NIST; Bethesda, 
MD), the DoD and other science agencies, to identify preservation as one of the key bottlenecks in tissue 
engineering efforts4,100,101. For instance, a new Advanced Tissue Biofabrication Manufacturing Innovation 
Institute (ATB-MII) announced at the ‘White House Organ Summit’ has a major focus on advancing organ 
preservation106; the solicitation calls for preservation technologies to enable biomanufacturing to move from un-
scalable, just-in-time manufacturing to scalable models using off-the shelf tissues101. Likewise, potential future 
initiatives under the Defense Innovation Unit-Experimental (http://www.diux.mil) in the areas of biofabrication, 
tissue engineering, regenerative medicine, and tissue-based chip devices will all likely require capabilities 
emerging from organ and tissue preservation advances. 
Restoration of reproductive tissue in cancer patients. Organ and tissue banking could also become a 
staple of cancer care for children and young adults. Ovary, uterus, and testis banking could be used to restore 
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fertility and hormone balance to the 140,000 childhood and young adult cancer survivors in the United States 
each year20,108,121–123 and hundreds of thousands more each year worldwide. Reproductive organs are highly 
sensitive to injury from chemotherapy and radiation, often leaving survivors of childhood and young adult 
cancer infertile and with altered endocrine function, resulting in lifelong sexual and psychological side 
effects20,108,124. These complications could be prevented by saving and banking reproductive organs and tissue 
before treatment, then re-implanting them afterward20,21,125,126.  
Thus far, >60 healthy offspring have been born to women who banked ovarian tissue before their first 
sterilizing cancer treatment127–129. Recently, whole sheep ovaries have been cryopreserved and re-implanted, 
and the sheep have gone on to produce healthy offspring20. Additional research can make ovary banking 
clinically feasible and yield insights applicable to banking testicular tissue, whole testes, and larger organs. 
With >1 million survivors of childhood and young adult cancer living in the United States alone (spanning 
roughly two generations)124,130, it is reasonable to estimate that reproductive organ and tissue banking could 
become the standard of care for millions of future cancer patients worldwide in the coming decades. 
Countermeasures for emergency preparedness. Advances in the preservation of many tissues are 
needed for trauma care, particularly to incorporate regenerative medicine therapies into strategic national 
stockpiles maintained by the United States’ interagency Public Health Emergency Medical Countermeasures 
Enterprise (PHEMCE; Washington, DC) for natural disasters, nuclear accidents or attacks, chemical and 
biological weapons, and other large-scale public health threats. For instance, radiological threats stemming from 
nuclear accidents or attacks have led the Biomedical Advanced Research and Development Authority 
(BARDA; Washington, DC), charged with procuring medical countermeasures for the strategic national 
stockpile, to search for measures that can treat radiation injury131. A 10 kiloton nuclear blast could cause acute 
radiation injury in >1 million people across a >10 mile radius. Large quantities of stockpiled bone marrow, cord 
blood and other sources of hematopoietic stem cells could be used either to permanently replace irreparably 
damaged bone marrow or to serve as a ‘bridge’ until the recovery of autologous hematopoiesis.132 The blast 
from such an event could cause burns and/or trauma combined with radiation exposure in over 45,000 
victims133, necessitating skin grafts for severe burns134,135, and blood vessel grafts for extremity injuries109. 
Similar needs for on-demand bone marrow and skin could also arise from the use of mustard gas or other 
exfoliants. Similarly, a large supply of banked human tissue—particularly liver, kidney, brain, or heart slices—
could be a critical resource for the rapid study of novel bioagents and development of medical countermeasures 
for biological and chemical terrorism threats. 
Tissue preservation and banking advances are needed to incorporate these and other treatments into 
strategic national stockpiles. For instance, precision-cut tissue slices can currently be cultured only for a matter 
of days, precluding standardization in preparation and on-demand use to address bioterrorism threats.136 
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Shortages of skin for use on-demand have led both BARDA and the US military to look for biomanufacturing 
solutions to stockpile large quantities of skin for combat or emergencies, yet for both groups short-tissue shelf 
life has been cited as a limiting factor18,109,135. Cryopreservation has enabled the banking and subsequent 
transplantation of both bone marrow and skin, but the current state of the art results in some loss of 
viability134,137. In the case of bone marrow banking, improvements to cryopreservation methods can also reduce 
the incidence of complications after transfusion137. Thus, preservation advances would help address large public 
health needs for these tissues. For entities, such as the DoD and BARDA to successfully leverage advances in 
regenerative medicine, preservation research is a necessity; the nature of emergency response dictates that 
banked tissues must be available for off-the-shelf use.  
Transplantation for acute injuries. Preservation advances could also dramatically increase patient 
access to transplantation or recovery of vascularized composite tissues, such as limbs, hands, or faces after 
traumatic injury. For example, roughly 30,000 traumatic amputations per year occur in the United States, over 
two thirds in children and young adults; it has been estimated that there will be >900,000 survivors of traumatic 
amputation living in the United States by 2020 (ref. 112). 
Extending preservation capabilities for recovered limbs can allow a greater number to be reattached, and 
in the past 15 years it has become possible to transplant hands, faces, and whole limbs from deceased donors37–
39,153. Although ample donor pools are already available, these procedures are still not routine—largely because 
of short matching windows (for both cosmetic and immunological criteria) and the risks of 
immunosuppression153. As discussed, preservation can address both of these challenges, playing a pivotal role 
in providing access to hand, limb, and face transplantation for tens of thousands of new patients each year.  
 
A dual, integrated approach to preservation 
 
A growing body of evidence indicates that a transformation in organ and tissue preservation is now achievable. 
Recent promising discoveries include organ cryopreservation and sub-zero cooling, perfusion, interventions 
before organ and tissue recovery, and adaptations that allow dozens of species in nature to enter ‘suspended 
animation’ at sub-freezing temperatures (e.g., see Table 4). Together, these approaches form a blueprint for a 
leap forward in preservation capabilities, centered on a combination of two promising strategies:  
 
1. Providing organ ‘life support’ by recapitulating aspects of the organ’s healthy physiological 
environment  
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2. Effectively ‘controlling biological time’ by slowing or halting metabolism to decrease rates of 
deterioration. 
 
Progress on both fronts is needed because each preservation approach involves tradeoffs often requiring the 
application of combined strategies in the same organ or tissue. For instance, slowing organ deterioration for 
extended preservation periods can be achieved by lowering organ temperature and metabolic rates, but this also 
entails the loss of normal organ function and opportunities for beneficial interventions, such as organ 
assessment, repair, and functional augmentation (Table 2). 
 Thus, we must begin to think about the aim of preservation not as the pursuit of a singular ‘best’ 
environment to keep a particular organ or tissue healthy on its way to transplantation (or use in research), but as 
an ‘integrated’ process during which the organ or tissue traverses multiple preservation conditions and 
temperature ranges that are used synergistically (Fig. 4). To make an integrated approach to preservation 
successful, we must combine and advance a family of research areas that includes cryopreservation5 
programmed metabolic suppression33, sub-zero preservation and supercooling154 perfusion and ex-vivo 
maintenance at a variety of temperatures, ranging from hypothermia (refrigeration) to normothermia (body 
temperature)23,24,26,155, and donor management before organ and tissue recovery138,142,143. The discoveries noted 
in Table 4 have provided various proofs of principle for using these approaches in organ and tissue 
preservation. They have historically been relatively siloed, despite the fact that they are complementary and 
often synergistic4,5,19,29,33,77,82,138. 
Advancing organ and tissue preservation through an integrated approach has become an achievable goal, 
as the past decade has seen an explosion of technologies enabling us to understand and intervene in human 
physiology at the tissue and organ level. Advances in cellular and tissue imaging156–158, organoids, organs on a 
chip and regenerative medicine13, high-throughput assays and sequencing readouts159, miniaturization and 
microfluidics160, nanotechnology161 and molecular engineering and gene editing162–168 can all be harnessed to 
galvanize research into the fundamental biology of tissue and organ cryopreservation, discover novel 
cryoprotectants, and develop new preservation strategies. This creates exciting prospects for translating the 
‘suspended animation’ programs of animals, such as the arctic ground squirrel169 and even tardigrade170, into 
tools for organ and tissue preservation. This decade has also seen rapid advances in ex vivo perfusion 
platforms22,23,25–27,30,57, which can be adapted to recapitulate aspects of an organ’s in vivo environment, 
condition it for storage or transport in a hypometabolic state, or enhance recovery from stresses experienced 
during donor death or the preservation period29,171–174. By building on, and marrying, these innovations in 
different disciplines, we are now poised to create a new generation of organ and tissue preservation capabilities 
driven both by public and by private sector funding (see Box 1).  
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Catalyzing breakthroughs 
 
So far, the very features that make preservation a foundational and high-impact research area have hindered its 
progress in the absence of coordinated support. The vast need to increase organ and tissue availability is spread 
across many areas of medicine and public health (Table 3)—and ultimately stakeholder groups. For instance, 
over 80% of NIH’s budget goes to institutes with missions tied to unmet preservation needs, encompassing 15 
different institutes110. This makes organ and tissue preservation research a nearly universal concern but no 
major funding body’s focus.  
The research expertise needed is similarly dispersed. Organ and tissue preservation is quintessentially 
‘convergence technology,’ integrating device engineering, applied mathematics, organic and inorganic 
chemistry, thermodynamics and biophysics, biochemistry and chemical biology, materials science, 
nanotechnology and molecular engineering, as well as molecular and cell biology4,175,176. This creates special 
challenges, as the institutions supporting science and engineering research have historically been divided 
according to research discipline175. For example, it can be inherently difficult to fund an ambitious preservation 
project because of the inability to assemble an NIH study section that can address all aspects of such a cross-
disciplinary grant proposal—even if all the research expertise to propose such a project comes together in the 
first place. The nature of organ and tissue preservation demands coordination among a large number of actors 
spanning many research communities, science agencies, industries, and stakeholder organizations. 
This coordination is beginning to take shape. For instance, the NSF-supported technology roadmapping 
process for organ banking and bioengineering, involving representatives from multiple agencies, including NIH, 
NSF, the US Food and Drug Administration (FDA; Rockville, MD), the DoD and other agencies along with 
dozens of academic institutions, identified >20 surrounding research areas that can be applied to accelerate 
progress on organ cryopreservation and recommended scientific and institutional strategies to enable organ 
banking4. Similarly, two US Health Resources and Services Administration (HRSA; Washington, DC)-funded 
consensus conferences recently identified untapped opportunities for in situ preservation of organs through 
donor management177. This set the stage for a National Academy of Medicine (Washington, DC) study this year 
aiming to develop a national infrastructure that will foster donor management research in the United States. At 
the June 2016 White House Organ Summit106, the Organ Preservation Alliance (of which S.G. and J.K.K. are 
directors) announced that it is leading a coalition of organizations to study the public health needs, scientific 
opportunities, and institutional challenges in advancing organ and tissue preservation. These stakeholder 
groups, which to date include the Association of Organ Procurement Organizations (McLean, VA), the 
American Society of Mechanical Engineers (New York, NY), the Society for Cryobiology (Luton, UK), and 
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others, will work together to craft a cohesive strategy to advance organ and tissue preservation on all fronts178. 
The need for a concerted effort to remove logistical barriers in organ and tissue replacement has also been 
emphasized in international efforts, for instance in a recent strategic plan for organ and tissue donation in 
Canada developed by more than 140 stakeholder organizations179. 
Initiatives aiming to encourage coordination have already born fruit in the form of collaborative research 
efforts that have sprung up around them. Last year, three DoD small business grant solicitations were targeted 
toward complex tissue preservation and banking180–182 (to the authors’ knowledge, the first US grant 
solicitations on this topic) yielded applications from 35 teams consisting of >100 labs across industry and 
academia—a virtually unprecedented response for the funding mechanism used. The DoD increased its support 
with three more grant solicitations in 2016109,183,184, largely as a result of the abundance of strong proposals 
during the previous year from cross-disciplinary teams 
Although this demonstrates the wealth of untapped opportunities in organ and tissue preservation 
research, active and centralized networking among research labs also played a substantial role in the strong 
response. Another successful effort to bolster research coordination is the Charlotte Banks research initiative at 
University of North Carolina, Charlotte, which developed out of discussions at the first global Organ Banking 
Summit in 2015 in Washington, DC. The initiative aims to cryopreserve living thick tissues by coordinating 
research among almost a dozen labs in vascular biology, nanotechnology, materials science, machine perfusion, 
computational physics, thermodynamics, and other areas (http://www.charlottebanks.org).  
Beyond these promising first steps, several additional mechanisms could be used to accelerate progress. 
Ambitious but achievable preservation challenges, such as large-scale tissue cryopreservation, may be a good fit 
for high-stakes, high-publicity incentive prize funding. A standing committee comprising experts and 
stakeholders from diverse fields is needed to coordinate organ and tissue preservation research. Finally, the 
challenge of increasing organ and tissue availability (which includes donation, preservation, manufacturing, and 
transplantation) is ideally suited for a national or international initiative on the scale of the BRAIN Initiative or 
Human Genome Project—given the inherent complexity of the remaining scientific challenges and the 
coordination needed, the increasingly important role of regenerative medicine, and the enormous potential of 
organ and tissue replacement to impact human health. 
The remaining challenges of organ and tissue preservation have become fertile ground for the 
application of existing knowledge, talent and research tools. Opportunities abound for diverse (and often 
converging) fields to provide innovative solutions, but institutional challenges remain and mechanisms to 
facilitate wider collaboration are needed. If we meet these challenges and build on the scientific proofs of 
principle that already exist, we may enter a new era of organ and tissue preservation in the coming years—
benefiting millions of patients globally and changing the course of many domains of public health. 
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Box 1. Burgeoning public and private sector interest in preservation  
The White House recently announced an upcoming ‘Summit on Organ Banking through Converging 
Technologies’ to be held at the Harvard Medical School’s Martin Conference Center in August 
(http://obs2017.obs2017.org/en/). This will be the first scientific consensus-building conference to map out how 
these and other technologies can be applied systematically to overcome remaining organ preservation 
challenges. Both basic and translational preservation research seems to be positioned to benefit from rapidly 
advancing platform technologies. Indeed, the past 3 years have seen a wave of new biotech companies in the 
organ and tissue preservation space, capitalizing on a small fraction of the opportunities that have emerged. 
Supported by multiple grant solicitations from the DoD and substantial funding from NIH, these firms are 
pursuing strategies, such as programmed hypometabolism, biomimetic nanoscience, radiofrequency-based 
‘nanowarming,’ isochoric preservation, subnormothermic perfusion and high-subzero temperature 
preservation185–190. Much of the current focus is on banking and subzero preservation; in this respect, the 
synergy between these technologies and ex vivo perfusion platforms (see Tables 2 and 4)4,5,19,29,30,77,82 means 
they benefit from—and enhance the value of—the substantial investments made in ex vivo perfusion in recent 
years191–194. 
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Figure 1. The true lifesaving potential of organ transplantation. The roughly 50,000 U.S. patients added to 
transplant waitlists in 2011 were outnumbered over 14-fold by those who died from end-stage organ disease 
(perfusix.com/impact-of-ex-vivo), without counting cases where malignancies could have been treated with 
organ replacement195. This suggests that the true size of the organ shortage could be many times larger than is 
reflected by transplant waitlists (currently 120,000 U.S. patients). 
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Figure 2. The global unmet need for transplantation greatly exceeds that of the United States (see Fig. 1), 
which contains roughly 4% of the world’s population but performs 25% of its organ transplants. By 
comparison, the continent of Africa contains roughly 16% of the world’s population but performs fewer than 
0.5% of its organ transplants (http://www.transplant-observatory.org/summary/; 
https://esa.un.org/unpd/wpp/publications/files/key_findings_wpp_2015.pdf) 
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Figure 3. 10-year graft survival curves for each of the six vital organs currently transplanted (single-organ, 
deceased donor transplant) 48. 10-year survival rates for organs range from slightly over 50% (hearts and livers) 
to slightly over 25% (lungs and intestine). These data indicate that ensuring transplant organ quality and 
reducing susceptibility to chronic rejection are still major challenges in transplantation. Preservation advances 
present diverse opportunities to meet these challenges (Table 2). 
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Figure 4. An integrated approach to organ and tissue preservation would combine multiple preservation 
conditions and temperature ranges, drawing on the strategies found in Table 4. Thus, when called for, differing 
preservation modalities could be used during successive stages of the preservation process, accessing a much 
wider range of temperatures and conditions than are currently used in conventional organ preservation. For 
instance, transplant organs could be held at subnormothermic temperatures during pharmacological pre-
conditioning for cryopreservation, then cooled to cryogenic temperatures for transport or banking, then returned 
to near-normothermic temperatures for functional assessment. Many combinations are conceivable based on the 
diverse “proof of principle” discoveries outlined above; the optimal preservation protocol will most likely vary 
according to tissue type and application. 
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*AU: WHAT IS THE SOURCE OF THESE NUMBERS FOR THE US IN 2012? 
  
Table 1. Summary picture for four vital organs from deceased donors* 
Vital organ 
Number 
transplanted66 
Percentage of 
organs not 
transplanted66 
HLA compatibility 
used in matching 
algorithms?88 
Ratio of unused organs to 
waitlist patients removed for 
death/illness44 
Heart 2,421 70% No 10:1 
Lung 3,019 81% No 32:1 
Kidney 11,993 26% Yes 3:5 
Liver 5,942 27% No 3:4 
37 
 
Table 2. Preservation enables key transplant capabilities 
  
Goal Capabilities 
Increasing pool of donor organs Reducing organ discard 
Rescuing marginal organs 
Decreasing costs of transplantation 
New matching approaches in deceased donation 
Successive organ transplants in case of graft dysfunction 
Enhancing transplant viability and function Repairing organ injury during removal and transport  
Assessing organ function before transplant 
Enabling new immune tolerance induction strategies 
Transmissible disease screening for donors and organs 
Augmenting organs (e.g., gene therapy, 
immunomodulation) 
New donor−recipient compatibility assessment methods 
Preventing ischemic injury during transplant 
Expanding transplantation access Extending live kidney donation chains 
Enabling recipients with acute disease or trauma 
Flexible scheduling of transplant surgeries 
Galvanizing research Accelerating progress in cryobiology and preservation 
Accelerating progress in humanized xenotransplantation 
Accelerating progress toward lab-grown organs 
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Table 3. Unmet needs for organ preservation 
 
  
Area of biomedicine Example of public health need 
Organ transplantation 
Almost 70% of US donor hearts go untransplanted, largely due to preservation 
limits on assessment and matching2,27,70,83,107 
Cancer treatment and 
fertility 
Ovary banking can save fertility/hormone balance in 140,000 girls and young 
women diagnosed with cancer and potentially exposed to chemo- and 
radiotherapy in the United States each year 108 
Emergency preparedness 
Banked bone marrow and cord blood could benefit >10,000 patients after a 
nuclear accident or attack109,110 as well as 14,000 US patients each year suffering 
acute injury AU:OK? who would benefit from a transplant111  
Limb recovery and 
transplantation 
30,000 traumatic amputations per year in United States; two thirds of victims are 
children and young adults112 
Basic medical research 
Human tissue would be a superior model to the 100 million mice and rats used in 
research each year113; tissue banking advances are critically needed to aid 
approaches seeking to treat malignancies114, neurodegenerative diseases115, and 
other disorders 
Trauma care 
30,000 patients admitted to specialized US burn units each year116. After a 
nuclear accident/attack, estimated ~3% of the skin grafts required would 
currently be available117. 
Tissue engineering and 
regenerative medicine 
Shelf-life of regenerative medicine products, a sector with a predicted > $500 
billion market by 2025 (ref. 118)  
Drug discovery 
Banked human tissue would benefit pre-clinical drug testing and potentially 
improve low efficiency of drug development119,120. 
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Table 4. Proof of principle already exists for each pillar of organ and tissue preservation. 
Approach Examples of proof of principle discoveries 
 
In situ organ 
preservation 
 Mild hypothermia in deceased kidney donors shown to reduce delayed 
graft function138 
 Hypothermic blood substitution protects from prolonged ischemia in 
trauma models139–141  
 Donor treatment with dopamine decreases kidney rejection and 
improves graft survival142 
 Cooperative donor management has been associated with increased 
organs transplanted143 
 
Ex vivo organ  
life support 
 Hypothermic perfusion devices have improved kidney preservation 
outcomes22–24,26 
 Normothermic machine perfusion used in hundreds of heart27 and lung 
transplants25,144,145 
 Subnormothermic machine perfusion used as platform for assessment,81 
cooling,29 etc.   
 Ex vivo perfusion successfully used as platform to repair marginal 
organs58 
 
 
 
High subzero  
preservation 
 At least 45 supercooling species (including mammals) tolerate 
temperatures as low as −14°C146 
 Arctic wood frog can enter suspended animation as low as −20°C for 
weeks to months31 
 Rabbit kidneys successfully cooled to −45°C before transplantation, 
sustaining life19 
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 Supercooling at −6°C has extended liver preservation times three- to 
fourfold in rats29,56 
 
 
 
Programmed 
metabolic 
suppression 
 Arctic wood frog, mammals, other species can initiate regulated 
metabolic arrest31,33 
 Genetic and biochemical studies have revealed mechanisms conserved 
in humans32–34 
 Pharmacologically induced ‘suspended animation’ has been 
demonstrated in mammals147 
 
Cryopreservation 
 >60 healthy human offspring conceived from cryopreserved ovarian 
tissue148,149 
 Cryopreserved whole sheep ovaries have been transplanted, producing 
healthy offspring20 
 Rabbit kidney successfully cryopreserved at –140°C  and transplanted, 
supporting life59 
 Human cells, embryos and some tissues have been cryopreserved for 
decades4,5  
 Ice-free cryopreservation has led to breakthroughs in banking of tissues 
for transplantation (e.g., blood vessels, cartilage and corneas)150–152 
 Research community has codified remaining sub-challenges for organ 
cryopreservation4,5  
